Global Small Molecule CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Small Molecule CDMO Market is presumed to reach the market size of nearly USD 137.98 BN by 2032 from USD 68.23 BN in 2023 with a CAGR of 8.14% under the study period 2024 - 2032.

Small Molecule Contract Development and Manufacturing Organizations (CDMOs) are companies that provide services related to the development, manufacturing, and sometimes testing of small molecule drugs. Small molecules are typically low molecular weight compounds that are used as active pharmaceutical ingredients in drug formulations. CDMOs offer expertise and infrastructure for the production of these small molecule drugs on behalf of pharmaceutical and biotechnology companies.

MARKET DYNAMICS

The Small Molecule Contract Development and Manufacturing Organization (CDMO) market is propelled by several factors reflecting the evolving landscape of the pharmaceutical industry. Increasing outsourcing trends in drug development and manufacturing, driven by a desire for cost efficiency and specialized expertise, contribute significantly to the demand for Small molecule CDMO services. The growing complexity of small molecule drug development, coupled with the rise in drug pipelines, prompts pharmaceutical companies to seek external partners for chemical synthesis, process optimization, and regulatory compliance. Focus on core competencies, cost-effective solutions, and the globalization of pharmaceutical manufacturing further fuel the market. Small molecule CDMOs offer flexibility, scalability, and accelerated time-to-market, attracting companies looking to navigate the intricate stages of drug development efficiently. Technological advancements and the CDMOs' regulatory expertise also play pivotal roles, ensuring clients have access to state-of-the-art solutions and can navigate regulatory requirements seamlessly. As the pharmaceutical industry continues to evolve, the Small molecule CDMO market is expected to witness sustained growth, shaping the landscape of drug development and manufacturing partnerships.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule cdmo. The growth and trends of small molecule cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Active Pharmaceutical Ingredients (API)
Finished Drug Products

By Drug Type

Innovators
Generics

By Application

Oncology
Cardiovascular Disease
Central Nervous System (Cns) Conditions
Autoimmune/Inflammation
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule CDMO market include Lonza, Catalent, Inc., Thermo Fisher Scientific Inc., Cambrex Corporation, Bellen Chemistry, Siegfried Holding AG, Recipharm AB, Eurofins Scientific, Aurigene Pharmaceutical Services Ltd., CordenPharma International. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113289

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . SMALL MOLECULE CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Drug Type
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Active Pharmaceutical Ingredients (API) Historic and Forecast Sales by Regions
5.5 Finished Drug Products Historic and Forecast Sales by Regions

6 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY DRUG TYPE

6.1 Overview by Drug Type
6.2 Historical and Forecast Data
6.3 Analysis by Drug Type
6.4 Innovators Historic and Forecast Sales by Regions
6.5 Generics Historic and Forecast Sales by Regions

7 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY APPLICATION

7.1 Overview by Application
7.2 Historical and Forecast Data
7.3 Analysis by Application
7.4 Oncology Historic and Forecast Sales by Regions
7.5 Cardiovascular Disease Historic and Forecast Sales by Regions
7.6 Central Nervous System (CNS) Conditions Historic and Forecast Sales by Regions
7.7 Autoimmune/Inflammation Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE CDMO COMPANIES

9.1. Small Molecule Cdmo Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF SMALL MOLECULE CDMO INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Lonza
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Catalent Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Cambrex Corporation
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Bellen Chemistry
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Siegfried Holding AG
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Recipharm AB
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Eurofins Scientific
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Aurigene Pharmaceutical Services Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. CordenPharma International
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies